glp 1 news today glp-1 obesity drug updates New research is challenging long-held assumptions about A new wave of weight-loss

But these new results are interesting nonetheless especially for those who use oral GLP-1 medications for both weight loss and type 2 diabetes

These findings build on prior observations of GLP-1 RA switching during periods of supply constraint

In a study with 39 participants (BMI 30 kg/m 2 ), GLP-1RAs such as semaglutide and liraglutide, combined with standard weight management, led to significant weight loss and fewer headache days compared to controls, with lower acetazolamide doses [92]

EMPA-KIDNEY (Empagliflozin in Patients with Chronic Kidney Disease) showed that in patients with chronic kidney disease, empagliflozin leads to a lower risk of progression of kidney disease [29]

First, the PI3K/PKA/mTOR pathway activates hypoxia-inducible factor 1 (HIF-1)

Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with RYBELSUS Warnings and Precautions Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS